<DOC>
	<DOCNO>NCT00769704</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety treatment talimogene laherparepvec compare subcutaneously administer GM-CSF patient unresectable Stage IIIb , IIIc Stage IV melanoma . The efficacy endpoint study aim demonstrate overall clinical benefit patient treat talimogene laherparepvec compare GM-CSF .</brief_summary>
	<brief_title>Efficacy Safety Study Talimogene Laherparepvec Compared Granulocyte Macrophage Colony Stimulating Factor ( GM-CSF ) Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Males female age â‰¥ 18 year Stage IIIb , IIIc stage IV disease surgically resectable Injectable disease ( i.e . suitable direct injection use ultrasound guidance ) At least 1 injectable cutaneous , subcutaneous nodal melanoma lesion &gt; = 10 mm long diameter , multiple injectable melanoma lesion aggregate long diameter &gt; = 10 mm Serum lactate dehydrogenase ( LDH ) level less 1.5 x upper limit normal ( ULN ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prolongation International Normalized Ratio ( INR ) , Prothrombin Time ( PT ) , Partial Thromboplastin Time ( PTT ) result therapeutic anticoagulation treatment permit patient whose injectable lesion cutaneous and/or subcutaneous direct pressure could apply event excessive bleeding Clinically active cerebral bone metastasis . Patients 3 ( neurological performance status 0 ) cerebral metastasis may enrol , provide lesion adequately treat stereotactic radiation therapy , craniotomy , gammaknife therapy , evidence progression , required steroid , least two ( 2 ) month prior randomization Greater 3 visceral metastasis ( include lung metastasis nodal metastasis associated visceral organ ) . For patient &lt; 3 visceral metastasis , lesion &gt; 3 cm , liver lesion must meet Response Evaluation Criteria In Solid Tumors ( RECIST ) criteria stable disease least 1 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>OncoVEX^GM-CSF</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Stage IIIb , IIIc IV Disease</keyword>
	<keyword>oncolytic</keyword>
	<keyword>OncoVex</keyword>
	<keyword>T-Vec</keyword>
	<keyword>talimogene laherparepvec</keyword>
</DOC>